📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Arteris, Inc., together with its subsidiaries, provides semiconductor system intellectual property (IP) solutions in the United States, rest of the Americas, China, Korea, the rest of the Asia Pacific, Europe, and the Middle East. It manages on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. The company offers Network-on-Chip (NoC) IP Products, such as FlexGen, FlexNoC, and FlexWay, a non-coherent NoC IP; Ncore, a cache-coherent NoC IP; and CodaCache, a last-level cache. It also provides hardware security verification software products, such as Cycuity Radix-S to detect and remediate security issues in IP blocks and subsystems of an SoC; Cycuity Radix-M for hardware security verification emulation for system-level SoC and firmware; and Cycuity Radix-ST, a static security analyzer that identifies potential design weaknesses early in the development lifecycle, as well as SoC integration automation software solutions products, including Magillem Connectivity and Registers, and CSRCompiler. In addition, the company offers professional services, such as training, design assistance, and consulting; licensing services for software and intellectual properties; IP support and maintenance; and on-site support services. It serves the automotive, communications, enterprise computing, consumer electronics, and industrial markets. Arteris, Inc. was founded in 2003 and is headquartered in Campbell, California.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding AIP

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Jim Simons Renaissance Technologies LLC	69.4K	$1.1M	0.00%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management leads with record annual contract value plus royalties ($69.1M) and RPO growth (28% YoY), and highlights strategic win with AMD for FlexGen. They provide specific guidance ranges and acknowledge FX headwinds but no deal cancellations.

Q3 2025

Confident Specific

Management used precise figures (record $74.9M ACV+royalties, 24% YoY growth, 34% RPO growth) and named multiple new customers (Altera, AMD, Dream Chip, Nanoxplore) with specific use cases, projecting certainty in their trajectory.

Q4 2025

Confident Specific

Management repeatedly used phrases like 'records and milestones', '28% year-on-year increase', 'beating our guidance on all financial measures', 'strong customer adoption', and 'record high' across ACV, RPO, and royalties, projecting unambiguous confidence without hedging.

Q1 2026 latest

Confident Specific

Management uses definitive language such as 'record revenue, record royalties, record revenue backlog' and 'ACV plus royalties up 39% year-on-year'. They highlight specific upward guidance revisions and state that non-GAAP operating profit is expected as early as Q4 2026, indicating strong execution confidence.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. Management delivered a clean beat-and-raise quarter with record metrics across ACV+royalties, revenue, and royalties. The shift toward enterprise data center and AI chips is accelerating, providing a faster revenue cycle than traditional automotive deals. The path to non-GAAP profitability by Q4 is clearly laid out, and free cash flow is already positive. Key risks include the CFO transition and the need to sustain deal momentum in a volatile semiconductor cycle. Next quarter, investors should watch for Q2 revenue landing within or above the raised guidance and any updates on the profitability inflection. The early Cycuity traction and the record April deal flow are positive leading indicators.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Arteris Q1 2026: Record ACV+royalties $92.8M (up 39% YoY), revenue $22.9M (up 39% YoY), royalty up 67%

Revenue & Profitability

Q1 2026 total revenue was $22.9 million, up 39% YoY. Non-GAAP gross margin was 87%; GAAP gross margin 86%. Non-GAAP operating loss was $2.5 million; GAAP operating loss $9.3 million. Non-GAAP net loss $1.2 million ($0.03 per share); GAAP net loss $8.0 million ($0.17 per share). Remaining performance obligations (RPO) were $118 million (up 33% YoY). Free cash flow was negative $7.4 million, including ~$3 million in Cycuity acquisition costs. Guidance: Q2 revenue $23-24 million; full year revenue raised to $91-95 million (32% YoY midpoint); full year non-GAAP operating loss improved to $8.5-$4.5 million; full year free cash flow positive $5-9 million.

Outlook

Management sees continued strength in semiconductors and signs of an upward trend cycle, driven by AI integration across data centers, edge devices, and physical AI. 2/3 of customer engagements are in AI chips. The start of Q2 2026 was very strong, with April deal flow a record (4x larger than any previous April). Based on this momentum, the company raised full year guidance on revenue and operating income.

Growth Drivers

Key growth levers include AI chip design (enterprise computing/HPC/data center is the largest vertical for licensing), automotive (especially ADAS/autonomous driving, e.g., Renesas R-Car Gen5), aerospace and defense, and communications (5G/6G). Royalty revenue grew 67% YoY, with the number of customers reporting >$250k quarterly royalties increasing from one to three. New chiplet/multi-die system IP products are expected in production in H2 2026, targeting AI, HPC, and ADAS.

Balance Sheet & CapEx

Not discussed in this earnings call. Free cash flow guidance includes capital expenditure, but specific capex numbers or capacity plans were not mentioned. The company ended Q1 with $41.9 million cash and no debt.

Margins

Non-GAAP gross margin was 87% (GAAP 86%). Management is committed to limiting OpEx growth to 50% of revenue growth; G&A spending has grown at less than 1/4 the rate of revenue on a non-GAAP basis over three years. This has driven a 31 percentage point improvement in non-GAAP operating margin over that period. Full year non-GAAP operating loss guidance improved by $0.5 million, and the company expects to reach non-GAAP operating profitability by Q4 2026.

Key Risks

Not explicitly flagged by management. Analyst questions touched on design cycle timelines for hyperscaler and HBM chips (two to three years) and product life cycles, but management did not highlight specific risks.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Record Q2 results with 46% revenue growth and 44% increase in ACV plus royalties, driven by strong demand in AI, data center, and automotive segments. Raised full-year guidance and expect non-GAAP profitability as early as Q4 2026.

Q1 2026 Q1 2026 2026-05-12

Record Q1 revenue and royalties, driven by AI and enterprise computing, led to raised 2026 guidance for revenue and profitability. Cycuity acquisition and strong customer engagement across verticals support growth, with non-GAAP profitability expected by Q4.

Q4 2025 Q4 2025 2026-02-12

Record annual contract value and royalties drove strong revenue and margin growth in 2025, with robust adoption across verticals and a major cybersecurity acquisition positioning for further expansion. 2026 guidance anticipates continued growth, improved profitability, and integration of Cycuity.

Q3 2025 Q3 2025 2025-11-04

Record Q3 results with 24% year-over-year ACV plus royalties growth, strong AI-driven demand, and major customer wins in automotive, industrial, and data center markets. Revenue and guidance exceeded expectations, with robust cash flow and no debt.

Q2 2025 Q2 2025 2025-08-05

Record Q2 results with 13% revenue growth and 28% RPO increase, driven by AI and chiplet demand. Secured a major AMD deal for FlexGen IP, expanded multi-die solutions, and launched new automation software. Guidance raised despite FX headwinds.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.